Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
$2.46
$2.95MN/AN/AN/A
Celyad SA stock logo
CYAD
Celyad
$0.60
$0.67
$0.46
$3.07
$15.91MN/AN/A3,009 shs
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
$2.70
+0.8%
$1.33
$0.89
$24.00
$12.09M2.161.60 million shs539,973 shs
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
$0.06
-4.4%
$0.11
$0.03
$10.79
$349K1.4247.88 million shs62.50 million shs
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$9.36
$9.36
$9.10
$12.00
$167.08M0.53600 shsN/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
Celyad SA stock logo
CYAD
Celyad
0.00%0.00%0.00%0.00%0.00%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-13.83%+120.58%+111.02%+92.81%-87.88%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-1.00%+8.35%-58.40%-92.04%-98.03%
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00%0.00%0.00%0.00%-22.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/AN/AN/AN/A
Celyad SA stock logo
CYAD
Celyad
N/AN/AN/AN/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1.2284 of 5 stars
0.05.00.00.02.80.00.6
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
2.5812 of 5 stars
3.32.00.00.01.12.51.3
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aravive, Inc stock logo
ARAV
Aravive
0.00
N/AN/AN/A
Celyad SA stock logo
CYAD
Celyad
0.00
N/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.00
N/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
2.50
Moderate Buy$25.0043,682.84% Upside
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aravive, Inc stock logo
ARAV
Aravive
$9.14M0.32N/AN/AN/A
Celyad SA stock logo
CYAD
Celyad
$200K79.56N/AN/A$0.02 per share30.00
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/A($2.11) per shareN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/A$1.34 per shareN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$6.82M24.50N/AN/A$0.21 per share44.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aravive, Inc stock logo
ARAV
Aravive
-$76.32MN/A0.00N/AN/AN/AN/AN/A
Celyad SA stock logo
CYAD
Celyad
-$6.30MN/A0.00N/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$15.75M-$78.00N/AN/AN/AN/AN/A-80.79%8/12/2025 (Estimated)
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$24.28M-$7.02N/AN/AN/AN/A-319.85%-88.55%8/13/2025 (Estimated)
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
-$17.63MN/A0.00N/AN/AN/AN/AN/AN/A

Latest NWPHF, MBIO, NCNA, ARAV, and CYAD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/2/2025Q1 2025
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$0.0129-$0.63-$0.6171-$0.63N/AN/A
5/14/2025Q1 2025
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A-$0.05N/A-$0.05N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/A
Celyad SA stock logo
CYAD
Celyad
N/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/A
Celyad SA stock logo
CYAD
Celyad
1.49
2.29
2.14
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A
1.34
1.34
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/A
1.25
1.25
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aravive, Inc stock logo
ARAV
Aravive
35.80%
Celyad SA stock logo
CYAD
Celyad
N/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
9.95%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
44.00%
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Aravive, Inc stock logo
ARAV
Aravive
60.40%
Celyad SA stock logo
CYAD
Celyad
0.94%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.21%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
31.20%
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aravive, Inc stock logo
ARAV
Aravive
2073.56 million29.13 millionNo Data
Celyad SA stock logo
CYAD
Celyad
9526.52 million26.28 millionNot Optionable
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1004.38 million4.37 millionNot Optionable
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
306.08 million4.18 millionNot Optionable
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
2217.85 millionN/ANot Optionable

Recent News About These Companies

Edison Issues Report on Newron Pharmaceuticals (NWRN)
Newron and Myung In Pharm sign agreement for evenamide development
Newron out-licenses evenamide in South Korea
Evenamide by Newron Pharmaceuticals for Schizophrenia: Likelihood of Approval
Newron out-licenses evenamide to Eisai unit EA Pharma

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aravive stock logo

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 07/9/2025

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Celyad stock logo

Celyad NASDAQ:CYAD

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Mustang Bio stock logo

Mustang Bio NASDAQ:MBIO

$2.70 +0.02 (+0.82%)
As of 10:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

NuCana stock logo

NuCana NASDAQ:NCNA

$0.06 0.00 (-4.36%)
As of 10:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Newron Pharmaceuticals stock logo

Newron Pharmaceuticals OTCMKTS:NWPHF

$9.36 0.00 (0.00%)
As of 07/8/2025

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.